several molecular technologies aimed at regulating gene expression that have been recently developed as a strategy to combat inflammatory and neoplastic diseases. among these, antisense technology is a specific, rapid, and potentially high-throughput approach for inhibiting gene expression through recognition of cellular RNAs. advances in the understanding of the molecular mechanisms that drive tissue damage in different inflammatory diseases, including Crohn's disease (CD) and ulcerative colitis (UC), the two major inflammatory bowel diseases (IBDs) in humans, have facilitated the identification of novel druggable targets and offered interesting therapeutic perspectives for the treatment of patients. this short review provides a comprehensive understanding of the basic concepts underlying the mechanism of action of the oligonucleotide therapeutics, and summarizes the available pre-clinical and clinical data for oligonucleotide-based therapy in IBD.

Di Fusco, D., Dinallo, V., Marafini, I., Figliuzzi, M., Romano, B., Monteleone, G. (2019). Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease. FRONTIERS IN PHARMACOLOGY, 10 [10.3389/fphar.2019.00305].

Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease

Marafini I;Monteleone G
2019-01-01

Abstract

several molecular technologies aimed at regulating gene expression that have been recently developed as a strategy to combat inflammatory and neoplastic diseases. among these, antisense technology is a specific, rapid, and potentially high-throughput approach for inhibiting gene expression through recognition of cellular RNAs. advances in the understanding of the molecular mechanisms that drive tissue damage in different inflammatory diseases, including Crohn's disease (CD) and ulcerative colitis (UC), the two major inflammatory bowel diseases (IBDs) in humans, have facilitated the identification of novel druggable targets and offered interesting therapeutic perspectives for the treatment of patients. this short review provides a comprehensive understanding of the basic concepts underlying the mechanism of action of the oligonucleotide therapeutics, and summarizes the available pre-clinical and clinical data for oligonucleotide-based therapy in IBD.
2019
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/12
Settore MEDS-10/A - Gastroenterologia
English
Di Fusco, D., Dinallo, V., Marafini, I., Figliuzzi, M., Romano, B., Monteleone, G. (2019). Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease. FRONTIERS IN PHARMACOLOGY, 10 [10.3389/fphar.2019.00305].
Di Fusco, D; Dinallo, V; Marafini, I; Figliuzzi, M; Romano, B; Monteleone, G
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Di Fusco, Front Pharmacol 2019.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 517.86 kB
Formato Adobe PDF
517.86 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/390164
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 91
  • ???jsp.display-item.citation.isi??? 84
social impact